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BSTRACT
Background:
 
The diagnosis of allergic diseases with
recombinant allergens allows us to detect antibodies
specific for single allergens in extracts. The aim of the
present study was to assess the early effect of grass
pollen immunotherapy on IgE and IgG4 responses to
eight purified grass pollen allergens in patients under-
going hyposensitization treatment.
 
Methods:
 
The sera of 22 consecutive atopic individ-
uals undergoing cluster regimen grass pollen immuno-
therapy were analyzed for IgE and IgG4 antibodies
specific for grass pollen allergens (Phl p 1, 2, 4, 5, 6,
7, 11, 12). Two serum samples were taken, one before
the start of therapy and one between 12 and 15 weeks
after the first immunization. Immunotherapy was per-
formed with two allergy vaccines comprising a stand-
ardized extract aluminum-adsorbed grass pollen mix
and a standardized extract of grass pollen mix adsorbed
onto calcium phosphate.
 
Results:
 
One treated patient showed a specific IgE
conversion from negative (< 0.35 kUA/L) to positive in
the capsulated hydrophilic carrier polymer (CAP) test
for Phl p 2, 1 and 4 (1.89, 0.84 and 0.68 kUA/L,
respectively). The sera of 10 of 11 patients treated with
alluminum-adsorbed grass pollen extract showed a
significant increase in specific IgG4 towards natural
Timothy grass pollen extract and purified allergens,
as well as significant IgG4 levels towards Phl p 1
(
 
P
 
 = 0.000238) Phl p 2 (
 
P
 
 = 0.000289), Phl p 4
(
 
P
 
 = 0.000585), Phl p 5 (
 
P
 
 = 0.000364), Phl p 6
(
 
P
 
 = 0.000346) and Phl p 11 (
 
P
 
 = 0.039623; Mann–
Whitney 
 
U
 
-test) 12 weeks after the onset of immuno-
therapy. The sera of seven of 11 subjects treated with
calcium phospate-adsorbed grass pollen extract had
significant IgG4 levels against Timothy pollen aller-
gens, as well as significant IgG4 titers against Phl p 1
(
 
P
 
 = 0.004703), Phl p 4 (
 
P
 
 = 0.000282), Phl p 5
(
 
P
 
 = 0.015480), Phl p 6 (
 
P
 
 = 0.013012) and Phl p 11
(
 
P
 
 = 0.005178). Patients treated with aluminum-
adsorbed grass pollen extract had higher levels of
IgG4 towards Phl p 2, 4 and 6 and natural Timothy
grass extract compared with patients treated with
calcium phosphate-adsorbed grass pollen extract.
Both the alluminum-adsorbed and calcium phos-
phate-adsorbed grass pollen extract allergy vaccines
induced significant titers of specific IgG4 towards
 
Phleum pratense
 
 pollen extract (
 
P
 
 = 0.008376 and
0.01148, respectively).
 
Conclusions:
 
These results indicate that grass pollen
immunotherapy elicits an array of antibody specifici-
ties that reflect the allergen content and the potency of
allergen extracts; this could be of pivotal importance to
define optimal allergen extract doses.
 
Correspondence: RE Rossi, Unità di Immunoallergologia, Via
Ospedali 14, 12038 Savigliano, Italy.
Email: immunoway@libero.it
Received 18 December 2001. Accepted for publication
17 June 2002.
 234 RE ROSSI 
 
ET AL.
 
Key words:
 
 allergen immunotherapy, IgE grass pollen
allergy, IgG4 subclass, recombinant allergens.
 
I
 
NTRODUCTION
 
The usefulness of specific immunotherapy (SIT) has been
highlighted in a recent World Health Organization report
that advocates its use in patients with specific IgE
antibodies to clinically relevant allergens.
 
1
 
 In patients
allergic to grass pollen, treatment is usually performed
with mixtures of different grass species. The rationale
behind this approach is to cover the spectrum of grass
pollen allergens as completely as possible.
 
2
 
 There is
evidence that SIT is effective in the prevention of allergic
asthma in children.
 
3
 
 Recently, it was reported that grass
pollen SIT improves quality of life in seasonal allergic
rhinitis and reduces seasonal asthma symptoms and
bronchial hyperresponsiveness.
 
4
 
It is well established that hyposensitization treatment
induces allergen-specific IgG4 antibodies.
 
5,6
 
 It was sug-
gested that blocking antibodies belonging to the IgG4
subclass may be induced by specific immunotherapy.
 
5
 
However, several studies failed to correlate the increase
of allergen-specific IgG4 levels with successful SIT.
 
7
 
 In
contrast, previous studies on the role of allergen-specific
IgE and IgG4 responses were hampered by the lack of
well-defined allergen extracts. Recombinant allergens
(RA) have now become available for antibody measure-
ments with defined components.
The aim of the present study was to analyze data
obtained by measuring the recognition of defined (i.e.
recombinant) allergens by serum IgE and IgG4 anti-
bodies in the early phase of SIT in patients undergoing
cluster regimen hyposensitization therapy.
 
M
 
ETHODS
 
Patients
 
Twenty-two consecutive patients, age range 16–40 years
(A1–11) and 5–56 years (P1–11), who were allergic to
grass pollen, as confirmed by a wheal size of at least
4 mm in the skin prick test, were evaluated. All patients
had typical symptoms of rhinoconjunctivitis and/or asthma
in the grass pollen season from April to July and specific
IgE against Timothy pollen extract (Table 1). Patients
were excluded from the study if they had received SIT in
the preceding 5 years.
 
Study design
 
Treatment of patients started in November 2000 and
observations were continued until November 2001.
Two serum samples were taken at the start of therapy
(November/December) and preseasonally (March) in the
first year of therapy.
All patients were symptomless before and 2 weeks
after the last injection of allergen extract. Two different
groups were included in the study. Both groups contained
sera from 11 patients.
Treatment was performed with Alutard
 
®
 
 Grassmix-5
SQ (ALK-Abello, Hørsholm, Denmark; patients A1–11)
and Phostal
 
®
 
 Grassmix-3 (Stallergenes, Antony, France;
patients P1–11).
 
Immunotherapy protocol
 
Active treatment involved either Alutard SQ
 
®
 
, a stand-
ardized aluminum-adsorbed extract of grass pollen mix
(
 
Dactilis glomerata
 
, 
 
Festuca pratensis
 
, 
 
Lolium perenne
 
,
 
Phleum pratense
 
 and 
 
Poa Pratensis
 
) or Phostal
 
®
 
, a stan-
dardized extract of grass pollen mix (
 
D. glomerata
 
,
 
P. pratense
 
 and 
 
P. pratensis
 
) adsorbed onto calcium
phosphate.
A modified ‘cluster’ regimen of injections of Alutard
SQ
 
®
 
, with once weekly visits for 5 weeks, was performed
(Table 2), followed by 3 weeks of maintenance injections.
Each 1 mL maintenance injection of 100 000 standard
quality units (SQU). Was equivalent to 10 000 biologic
units
 
8
 
 and contained approximately 2.4 
 
µ
 
g Dag g 5,
3.7 
 
µ
 
g Fes p 5, 2.50 
 
µ
 
g Lol p 5, 4.02 
 
µ
 
g Phl p 5 and
3.04 
 
µ
 
g Poa p 5 per 100 000 SQU. A similar ‘cluster’
regimen of injections of Phostal
 
®
 
 (approximately 8.5 
 
µ
 
g/
mL group 5 allergen) was performed (Table 3).
 
Table 1
 
Demographic and clinical data of the patients
Patients 
A1–11 P1–11
Sex (M/F) 5/6 7/4
Age (years)
Mean 28 26
Range 16–40 5–56
Diagnosis
Rhinitis (
 
n
 
) 2 3
Rhinitis and asthma (
 
n
 
) 9 8
 
Patients A1–11 received Alutard
 
®
 
 Grassmix-5 SQ (ALK-Abello,
Hørsholm, Denmark), whereas patients P1–11 received Phostal
 
®
 
Grassmix-3 (Stallergenes, Antony, France).
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Immunotherapy was performed by the same allergist
(RER), with full resuscitation facilities available. Local
cutaneous reactions at the injection site and any other
symptoms occurring within 5 h were documented.
 
In vitro
 
 assays
 
Serum-specific IgE and IgG4 were analyzed by the
Pharmacia CAP System (Pharmacia-Upjohn, Uppsala,
Sweden) according to the manufacturer’s instructions.
The sera were characterized in detail by determination of
IgE and IgG4 antibodies towards Phl p 1, 2, 4, 5, 6, 7,
11 and 12. Specific IgE/IgG against Timothy grass was
also measured.
 
Statistical analysis
 
Results are expressed as the median and 25th–75th
percentile. The non-parametric Mann–Whitney 
 
U
 
-test
and Wilcoxon test were used for statistical comparisons.
 
Table 2
 
Alutard
 
®
 
 cluster immunotherapy updosing and maintenance schedule
Visit no. Week Injection Concentration (SQU/mL) Volume (mL)
1 1 1 100 0.1
2 1000 0.1
3 10 000 0.05
2 2 4 10 000 0.2
5 10 000 0.2
3 3 6 10 000 0.5
7 100 000 0.2
4 4 8 100 000 0.4
9 100 000 0.4
5 5 10 100 000 0.5
11 100 000 0.5
6 6 12 100 000 1.00
7 9 13 100 000 1.00
 
Injections were given at 30 min intervals and patients were observed after the last injection of each cluster. Blood samples were taken before 
treatment and 2 weeks after the 12th injection.
SQU, standard quality units.
 
Table 3
 
Phostal
 
®
 
 cluster immunotherapy updosing and maintenance schedule
Visit no. Week Injection Concentration (IR/mL) Volume (mL)
1 1 1 0.1 0.1
2 0.1 0.2
3 0.1 0.2
2 2 4 1 0.1
5 1 0.1
3 3 6 1 0.2
7 1 0.2
4 4 8 10 0.2
5 9 10 0.2
6 5 10 10 0.4
11 10 0.4
7 6 12 10 1.00
8 9 13 10 1.00
9 13 14 10 1.00
 
Injections were given at 30 min intervals and patients were observed after the last injection of each cluster. Blood samples were taken before 
treatment and 2 weeks after 14th injection.
IR, index of reactivity.
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Patients were also evaluated with a mixed design analysis
of variance (ANOVA). P < 0.05 was considered significant.
RESULTS
Systemic reactions to SIT
Two mild systemic reactions were seen during the
induction period in the Alutard SQ®-treated group (one
sneezing, one mild wheezing with mild urticaria and
itching). During maintenance treatment, no delayed
systemic reactions were observed.
One mild systemic reaction was observed during the
induction period in one patient treated with Phostal®
(urticaria, itching). All patients continued with therapy
without further incident.
Clinical efficacy of SIT
Patients were asked to give their impressions of the
degree of improvement after 10–12 months of treat-
ment, on a scale of 0–3 (0, worsening; 3, remarkable
improvement). All patients, except for one treated with
Phostal®, declared an improvement in symptoms during
the pollen season. However, a double-blind placebo-
controlled study was not performed on these patients.
Timothy and Bermuda grass pollen-specific IgE 
antibodies and specific IgE towards purified 
allergens
All pre- and post-SIT sera (n = 44) were tested by the
CAP system for RA, native Phl p 4 and natural Timothy
grass-specific IgE (Fig. 1). The mean of the time interval
between the collection of the two samples was 13 weeks.
Before the onset of SIT, the sera of patients A1–11 and
patients P1–11 were homogeneous with respect to
specific IgE levels, as established by ANOVA (data not
shown) and the Mann–Whitney U-test (Fig. 1).
One treated patient showed a conversion from
negative (< 0.35 kUA/L) to positive in the CAP test
for Phl p 2, 1 and 4 (1.89, 0.84 and 0.68 kUA/L,
respectively).
Fig. 1 IgE levels towards purified allergens and natural extract before the onset of immunotherapy in 11 patients treated with
aluminum-adsorbed grass pollen extract (Alutard® Grassmix-5 SQ; ALK-Abello, Hørsholm, Denmark) and calcium phosphate-
adsorbed grass pollen extract (Phostal® Grassmix-3; Stallergenes, Antony, France; Mann-Whitney U-test).
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Fig. 2 Comparison of IgG4 responses at the onset of and 12 weeks after immunotherapy with aluminum-adsorbed grass pollen
extract in 11 patients allergic to grass pollen (Wilcoxon test). The amount of allergen administered during the 12 weeks was approx-
imately 65 µ
 
g group 5 allergen. A1–A11, patients 1–11.
Fig. 3 Comparison of IgG4 responses at the onset of and 15 weeks after immunotherapy with calcium phosphate-adsorbed grass
pollen extract in 11 patients allergic to grass pollen (Wilcoxon test). The amount of allergen administered during the 15 weeks was
approximately 40 µ
 
g group 5 allergen. P1–P11, patients 1–11.
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Timothy grass, Bermuda grass pollen and 
purified allergen-specific IgG4 measured by 
the CAP test
The titers of IgG4 directed against natural extracts and
RA (and native Phl p 4) were raised significantly in
treated patients compared with values measured before
the beginning of SIT (Fig. 2). We documented an increase
in IgG4 towards certain allergens in the sera that did not
seem to bind specific IgE before and after SIT (14/52;
26.9%). In these cases, post-SIT IgG4 levels did not
exceed 1.42 mg/L (value referred to Phl p 5). Alutard
SQ® induced significant titers of IgG4 towards Phl p 1
(P = 0.000238), Phl p 2 (P = 0.000289), Phl p 4
(P = 0.000585), Phl p 5 (P = 0.000364), Phl p 6
(P = 0.000346) and Phl p 11 (P = 0.039623), but not
Phl p 12 (P = 0.044310) and Phl p 7 (P = 0.288002).
Phostal® induced significant levels of IgG4 against Phl
p 1 (P = 0.0004703), Phl p 4 (P = 0.000282), Phl p 5
(P = 0.015480), Phl p 6 (P = 0.013012) and Phl p 11
(P = 0.005175), but not to the remaining purified aller-
gens. Both allergen extracts for SIT induced significant
titers of specific IgG4 towards Phleum pratense (Alutard
SQ® P = 0.008376; Phostal® P = 0.001148; Mann–
Whitney U-test).
The sera of 10 of 11 patients (A1–11) showed a signif-
icant increase in specific IgG4 towards natural Timothy
grass pollen extract and purified allergens (Fig. 2) after
12 weeks. The sera of seven of 11 subjects (P1–11) had
significant IgG4 levels against Timothy grass pollen aller-
gens 15 weeks after the first immunization (Fig. 3). At
least in the first phase of SIT, patients treated with
aluminum-adsorbed grass pollen extract had higher
levels of IgG4 towards Phl p 2, 4 and 6 and natural
Timothy grass extract than patients treated with calcium
phosphate-adsorbed grass pollen extract (Fig. 4)
Fig. 4 Median IgG4 levels of serum IgG4 towards purified allergens and natural Timothy grass pollen extract induced by with
aluminum-adsorbed grass pollen extract (Alutard® Grassmix-5 SQ; ALK-Abello, Hørsholm, Denmark) and calcium phosphate-
adsorbed grass pollen extract (Phostal® Grassmix-3; Stallergenes, Antony, France) in two groups of allergic patients (n = 11 each).
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DISCUSSION
In the present study, the safety profile of the two SIT
extracts administered in a modified ‘cluster’ regimen of
injections was good. Local swelling and some mild
systemic reactions, which were greater for Alutard SQ®-
treated subjects, were seen but were considered by the
allergist to be no worse than normally observed with
other allergy vaccine regimens. Previously published
results demonstrated a marked increase in allergen-
specific IgG and IgG4 antibodies in patients treated with
conventional subcutaneous SIT, whereas no significant
changes in the levels of allergen-specific IgE could be
observed.7,9 In agreement with Gehlhar et al.,10 we did
not find any influence of SIT on mean IgE levels, at least
in the earlier phase of immunization treatment. How-
ever, it is to be noted that other studies have shown an
increase in IgE at the beginning of SIT, followed by a
decline.11 In the present study, there was only one grass
pollen-allergic subject who had no detectable IgE
towards RA and native Phl p 4 at the beginning, but
this situation changed 15 weeks later. Although active
induction of new IgE specificities by SIT is not really
demonstrated, van Ree et al.12 have reported the
appearance of IgE with specificities not detected before
SIT in approximately 8% of patients. We observed this
phenomenon in a serum sample taken 15 weeks after
the start of therapy with Aspergillus extract (ALK-Abello,
Lainate, Italy) and 4000 nitrogen treatment units (NTU)
allergen administered. In this case, newly induced IgE
antibodies towards rAsp f 3 from negative (< 0.35 kUA/L)
to positive (15.1 kUA/L) were detected (RE Rossi et al.,
unpubl. obs., 2000).
In the present study, ‘new’ IgE antibodies were directed
to major allergens Phl p 2, 1 and 4. This certainly rep-
resents an undesiderable effect of SIT. However, IgE pro-
duction may be partially blocked by the induction of
specific IgG4 antibodies. Furthermore, allergen-specific
IgG antibodies may bind either to different epitopes or
with lower affinity compared with IgE antibodies.12,13
However, the induction of IgG antibodies by hyposensiti-
zation treatment was already noted early6,14 and the
blocking activity of such antibodies has been shown pre-
viously.15 In the present study, we did not investigate the
inhibitory effect of these antibodies towards IgE-mediated
reactions (i.e. reaction to purified allergen in vivo or hista-
mine release using purified allergens in vitro).
However, Vrtala et al. have shown that a Phl p 6 frag-
ment induces IgG antibodies, which bind to complete
Phl p 6 and inhibit the IgE of allergic patients binding to
Phl p 6.16
Until now, the measurement of IgG4 towards natural
allergen extracts has served to ascertain that the immune
system is responding to treatment. In a previous study,17
antibody titers directed against a crude allergen extract,
which contains many antigenic proteins besides the
relevant allergens, were measured. More recently, tests
were performed using purified allergens and these tests
showed that IgG antibodies that are allergen-specific are
relevant for the observed clinical changes. In fact,
Gehlhar et al.10 observed that the ratio of IgG4 to IgG1
could serve as a valuable parameter to assess the
success of immunotherapy already 1 year after the onset
of immunotherapy. Moreover, sera containing therapy
induced allergen-specific IgG antibodies were found to
suppress IgE-mediated presentations of allergens to
T cells and, thus, to reduce T cell proliferation and
cytokine release.18 Finally, blocking antibodies induced
by vaccination with Phl p 1 peptide: (i) reduces Phl p 1-
induced effector cell activation; (ii) prevents the produc-
tion of Phl p 1-specific IgE synthesis; and (iii) inhibits
IgE-mediated T cell activation.19
The cumulative dose administered with Alutard SQ®
and Phostal® (approximately 65 and 40 µg major group
5 allergen, respectively) was relatively high during the 14
weeks of therapy. This may explain the positive effect of
SIT on IgG4 production, particularly in patients treated
with Alutard SQ®. Moreover, the main implication from
the present study is that the allergen extracts for immuno-
therapy contain, as expected, relevant allergens recog-
nized by the immune system (i.e. Phl p 1, 2, 4, 6 and 11)
in addition to the group 5 allergen declared by the
manufacturers. Therefore, IgG4 measurements against
purified allergens allow us to monitor indirectly the
presence of relevant allergens of a particular SIT extract.
Given that a patient’s allergogram may be highly vari-
able,20,21 it may be useful to evaluate IgE and IgG anti-
bodies directed towards defined components in order
to adjust the dose of the vaccine administered during a
course of treatment.
Thus, IgE/IgG4 antibodies to well-definited allergens
can be followed up during the course of the disease and
the occurrence of IgE antibodies with new specificity
revealed and, possibly, antagonized with blocking anti-
bodies, which could be induced by a well-definited grass
pollen extract. In conclusion, for the sake of the best def-
inition of immunotherapeutics, the application of extracts
standardized by the content of the major allergen in
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µg/mL may be desiderable. It may be possible to improve
the quality of treatment by achieving individual doses of
RA mixture, through the use of RA variants with reduced
IgE reactivity, in the near future.
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